



Model List of Essential Medicines

Abiraterone

Section	Indications
Hormones and antihormones Oral > Solid: 250 mg; 500 mg	Malignant neoplasms of prostate

Aclidinium

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease

Adalimumab

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL	Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
Medicines for juvenile joint diseases Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL	Juvenile idiopathic arthritis

Afatinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

Alteplase

Section	Indications
Thrombolytic medicines Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection	Cerebral ischaemic stroke

Amodiaquine + sulfadoxine + pyrimethamine

Section	Indications
<p>Antimalarial medicines > For chemoprevention</p> <p>Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package</p>	Malaria

Amoxicillin

Section	Indications
<p>Access group antibiotics</p> <p>Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid</p> <p>Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection</p> <p>Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)</p> <p>Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)</p>	<p>First choice</p> <p>Periapical abscess without sinus</p>

Amoxicillin + clavulanic acid

Section	Indications
<p>Access group antibiotics</p> <p>Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection</p> <p>Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid</p> <p>Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)</p> <p>Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)</p>	<p>Second choice</p> <p>Other specified prophylactic measures</p>

Antituberculosis medicines

Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid	Multi-drug resistant Mycobacterium tuberculosis
Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	

Apixaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation

Aprepitant

Section	Indications
Antiemetic medicines Oral > Liquid: 125 mg powder for oral suspension (in sachet) Oral > Solid: 80 mg; 125 mg; 165 mg	Nausea or vomiting

Arsenic trioxide

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion	Acute myeloid leukaemia with recurrent genetic abnormalities

Azithromycin

Section	Indications
Watch group antibiotics Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)	First choice Typhoid fever Paratyphoid fever

Bortezomib

Section	Indications
Targeted therapies Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection	Plasma cell myeloma

Carbetocin

Section	Indications
Uterotonics Parenteral > General injections > IV: 100 µg per mL (heat stable)	Postpartum haemorrhage

Carbimazole

Section	Indications
Thyroid hormones and antithyroid medicines	Therapeutic equivalent to methimazole for Thyrotoxicosis

Carboplatin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL	Malignant neoplasms of cervix uteri

Cefazolin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection	First choice Other specified prophylactic measures co-prescribed with metronidazole Other specified prophylactic measures

Ceftazidime + avibactam

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection	Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacteriales

Ceftriaxone

Section	Indications
Watch group antibiotics Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)	First choice Typhoid fever Paratyphoid fever

Cefuroxime

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection	Second choice Other specified prophylactic measures

Certolizumab pegol

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab for Axial spondyloarthritis
Medicines for juvenile joint diseases	Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis

Ciprofloxacin

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 2 mg per mL (as hyolate) Oral > Liquid: 250 mg per 5 mL (anhydrous) Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)	First choice Typhoid fever Paratyphoid fever

Colistin (injection)

Section	Indications
Reserve group antibiotics Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)	Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales

Cyclophosphamide

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection</p> <p>Oral > Solid > dosage form: 25 mg; 50 mg</p>	Plasma cell myeloma

Dabigatran

Section	Indications
<p>Medicines affecting coagulation</p> <p>Oral > Solid: 110 mg; 150 mg</p>	Venous thromboembolism Other specified atrial fibrillation

Dengue vaccine

Section	Indications
<p>Recommendations for some high-risk populations</p> <p>All vaccines should comply with the WHO requirements for biological substances.</p>	Need for immunization against certain single viral diseases

Dexamethasone

Section	Indications
<p>Hormones and antihormones</p> <p>Oral > Solid: 4 mg</p> <p>Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphosphate salt)</p>	Plasma cell myeloma

Diazoxide

Section	Indications
<p>Medicines for hypoglycaemia</p> <p>Oral > Liquid: 50 mg per mL</p> <p>Oral > Solid: 50 mg</p>	Persistent hyperinsulinaemic hypoglycaemia of infancy

Dolutegravir + lamivudine + tenofovir

Section	Indications
<p>Fixed-dose combinations of antiretrovirals</p> <p>Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)</p>	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Doxorubicin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)	Plasma cell myeloma

Edoxaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for Vinous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation

Enzalutamide

Section	Indications
Hormones and antihormones	Therapeutic equivalent to abiraterone for Malignant neoplasms of prostate

Erlotinib

Section	Indications
Targeted therapies Oral > Solid: 100 mg; 150 mg	Other specified malignant neoplasms of bronchus or lung

Etanercept

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
Medicines for juvenile joint diseases	Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis

Fexinidazole

Section	Indications
Medicines for the treatment of 1st stage African trypanosomiasis Oral > Solid: 600 mg	African trypanosomiasis
Medicines for the treatment of 2nd stage African trypanosomiasis Oral > Solid: 600 mg	African trypanosomiasis

Fosfomycin (injection)

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection	Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacteriales

Gefitinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

Gentamicin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)	Second choice Other specified prophylactic measures

Glecaprevir + pibrentasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid: 50 mg + 20 mg granules Oral > Solid > tablet: 100 mg + 40 mg	Chronic hepatitis C

Glycopyrronium

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease

Golimumab

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
Medicines for juvenile joint diseases	Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis

Imipenem + cilastatin

Section	Indications
Antituberculosis medicines	Therapeutic equivalent to meropenem for Multi-drug resistant Mycobacterium tuberculosis

Infliximab

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
Medicines for juvenile joint diseases	Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis

Ivermectin

Section	Indications
Medicines for ectoparasitic infections Oral > Solid > tablet: 3 mg	Scabies

Lenalidomide

Section	Indications
Immunomodulators Oral > Solid: 25 mg	Plasma cell myeloma

Linezolid

Section	Indications
Reserve group antibiotics	Methicillin resistant <i>Staphylococcus aureus</i>
Parenteral > General injections > IV: 2 mg per mL in 300 mL bag	Vancomycin resistant <i>Staphylococcus aureus</i>
Oral > Liquid: 100 mg per 5 mL powder for oral liquid	Vancomycin resistant <i>Enterococcus</i>
Oral > Solid > dispersible tablet: 150 mg	
Oral > Solid > tablet: 600 mg	

Lisinopril + amlodipine

Section	Indications
Antihypertensive medicines Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg	Essential hypertension

Lisinopril + hydrochlorothiazide

Section	Indications
Antihypertensive medicines Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg	Essential hypertension

Melphalan

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial powder for injection Oral > Solid: 2 mg	Plasma cell myeloma

Meropenem

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Meropenem + vaborbactam

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection	Carbapenem-resistant <i>Pseudomonas aeruginosa</i> Carbapenem resistant <i>Enterobacteriales</i> Carbapenem resistant <i>Acinetobacter baumannii</i>

Methimazole

Section	Indications
Thyroid hormones and antithyroid medicines Oral > Solid: 5 mg; 10 mg; 20 mg	Thyrotoxicosis

Metronidazole

Section	Indications
Access group antibiotics Oral > Liquid: 200 mg per 5 mL (as benzoate) Local > Rectal > Suppository: 500 mg; 1 g Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg	First choice co-prescribed with cefazolin Other specified prophylactic measures

Multiple micronutrient powder

Section	Indications
Vitamins and minerals Sachets containing: - iron (elemental) 12.5 mg (as coated ferrous fumarate) - zinc (elemental) 5 mg - vitamin A 300 micrograms - with or without other micronutrients at recommended daily values	Iron deficiency anaemia

Nivolumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion	Melanoma of skin

Oral rehydration salts - zinc sulfate

Section	Indications
Medicines used in diarrhoea Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)	Diarrhoea

Paclitaxel

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 6 mg per mL	Malignant neoplasms of cervix uteri

Pegasparagase

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection	Lymphoid leukaemia, not elsewhere classified

Pembrolizumab

Section	Indications
Immunomodulators	Therapeutic equivalent to nivolumab for Melanoma of skin

Phenoxymethylenicillin

Section	Indications
Access group antibiotics Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)	First choice Periapical abscess without sinus

Plazomicin

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 500 mg per 10 mL	Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales

Polymyxin B (injection)

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)	Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales

Prednisolone

Section	Indications
Hormones and antihormones Oral > Solid: 5 mg; 25 mg	Plasma cell myeloma Malignant neoplasms of prostate

Prednisone

Section	Indications
Hormones and antihormones	Therapeutic equivalent to prednisolone for Plasma cell myeloma Therapeutic equivalent to prednisolone for Malignant neoplasms of prostate

Procarbazine

Section	Indications
Cytotoxic medicines Oral > Solid > capsule: 50 mg (as hydrochloride)	Hodgkin lymphoma

Realgar-indigo naturalis formulation

Section	Indications
Cytotoxic medicines Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)	Acute myeloid leukaemia with recurrent genetic abnormalities

Rivaroxaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation

Sulfadoxine + pyrimethamine

Section	Indications
Antimalarial medicines > For chemoprevention Oral > Solid: 500 mg + 25 mg tablet Oral > Solid: 250 mg + 12.5 mg tablet	Malaria due to Plasmodium falciparum Malaria

Tedizolid

Section	Indications
Reserve group antibiotics	Therapeutic equivalent to linezolid for Methicillin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Enterococcus

Telmisartan + amlodipine

Section	Indications
Antihypertensive medicines Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg	Essential hypertension

Telmisartan + hydrochlorothiazide

Section	Indications
Antihypertensive medicines Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg	Essential hypertension

Thalidomide

Section	Indications
Immunomodulators Oral > Solid: 50 mg	Plasma cell myeloma

Tiotropium bromide

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease Respiratory > Inhalation > dry powder: 18 µg capsule Respiratory > Inhalation > solution: 1.25 µg per actuation; 2.5 µg per actuation	Chronic obstructive pulmonary disease

Tranexamic acid

Section	Indications
Other medicines administered to the mother Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Postpartum haemorrhage

Umeclidinium

Section	Indications
Antiasthmatic and medicines for chronic obstructive pulmonary disease	Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease